The VIPE study was a prospective, non-comparative, open-label clinical evaluation of 97 hypertensive patients (69.1% female; 68.9±9.5 years; mean blood pressure (BP) 160±12/90±9 mmHg) with echocardiographic evidence of left ventricular hypertrophy (LVH). Patients were treated for six months with a candesartan-based regimen (8 mg/16 mg + HCTZ 12.5 mg + additional drugs to lower BP < 140/90 mmHg). After six months, systolic/diastolic BP was decreased by 19.3±8/9.4±5 mmHg (p<0.001 for both), and left ventricular mass index (LVMI) decreased 17.01 g/m2 (95%CI: -13.2 to -20.99; p<0.001). During treatment with the candesartan-based regimen all echocardiographic parameters related to LVMI were significantly reduced and 28% achieved a target LVMI [< 134 g/m2 (men) and < 110 g/m2 (women) ]. No significant changes were observed in ejection fraction, shortening fraction or LV diastolic function. Univariate analysis showed that both age (p=0.03) and diabetes (p=0.029) were predictive of LVH regression.
Thus, a candesartan-based regimen for six months significantly reduced echocardiographic LVH in hypertensive patients in general practice. The drug was very well tolerated and no serious adverse events were reported.
European Society of Hypertension-European Society of Cardiology Guidelines Committee.2003European Society of Hypertension-European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens2003;21:1011-53.
2.
Levy D., Garrison RJ, Savage DD, Kannel WB, Castelli WPPrognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med1990;322:1561-6.
3.
Verdecchia P. , Schillacci G., Borgioni C. et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation1998;97:48-54.
4.
Okin PM, Devereaux RB, Julius J. et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The LIFE Study. Circulation2003,108:684-90.
5.
Okin PM, Devereaux RB, Julius J. et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of mayor cardiovascular events. JAMA2004;292:2343-9.
6.
Verdecchia P. , Angeli F., Borgioni C. et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis . Am J Hypertens2003;16:895-9.
7.
Mathew J., Sleight P., Lonn E. et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation2001; 104:1615-21.
8.
Schneider MP , Klingbeil AU, Delles C. et al. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. Hypertension2004;44:61-6.
9.
Dahlof B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002;359:995-1003.
10.
Everett AD, Tufro-McReddie A., Fisher A., Gomez RAAngiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension1994 ;23:587-92.
11.
Yamakawa T. , Tanaka S., Numaguchi K. et al. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension2000;35:313-18.
12.
Dahlof B.Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens2001;14:174-82.
13.
Israili ZHClinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension . J Hum Hypertens2000;14(suppl 1):S73-S76.
14.
Klingbeil AV , Schneider M., Martus P., Messerli FH, Schmieder REA meta-analysis of the effects of treatment on left ventricular mass in essential hypertension . Am J Med2003;115:41-6.
15.
Cuspidi C., Muiesan ML, Valagussa L. et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens2002;20:2293-300.
16.
Devereux RB , Dahlof B., Gerdts E. et al. Regression of hypertensive left ventricular hypertorphy by losartan compared with atenolol. The Losartan Intervention For Endpoint reduction in hypertensive (LIFE) Study . Circulation2004;110:1456-62.
17.
Malmqvist K. , Kahan T., Edner M. et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens2001;19:1167-76.
18.
Trenkwalder P.Efficacy and tolerability of candesartan cilexetil in special patient groups. Blood Press (suppl)2000;1:27-30.
19.
Hashimoto Y. , Kurosawa Y., Minami K., Fushimi K., Narita H.A novel angiotensin II-receptor antagonist, 606A, induces regression of cardiac hypertrophy, augments endothelium-dependent relaxation and improves renal function in stroke-prone spontaneously hypertensive rats. Jpn J Pharmacol1998;76:185-92.
20.
Zannad F.Preserving target-organ function with candesartan cilexetil in patients with hypertension. Blood Press (suppl)2000 ;1:36-9.
21.
Isobe N., Taniguchi K., Oshima S. et al. Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ J2002;66:993-9.
22.
Easthope SE , Jarvis B.Candesartan cilexetil: an update of its use in essential hypertension. Drugs2002;62:1253-87. 23. Concato J., Shah N., Horwitz RIRandomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med2000;342:1887-92.
23.
Rosser WWApplication of evidence from randomised controlled trials to general practice . Lancet1999;353:661-4.
24.
Devereux RB, Reichek N.Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation1977 ;55:613-18.
25.
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Sachas I.Echocardiographic assessment of left ventricular hypertrophy comparison to necropsy findings. Am J Cardiol1986;57:450-8.
26.
Ganau A., Devereux RB, Roman MJ et al. Patterns of left ventricular hypertrophy and geometric remodelling in essential hypertension. J Am Coll Cardiol1992;19:1550-58.
27.
Nosir YF, Vletter WB, Boersma E. et al. The apical long-axis rather than the two-chamber view should be used in combination with the four-chamber view for accurate assessment of left ventricular volumes and function. Eur Heart J1997;18:1175-85.
28.
Sokolow M., Lyon TPThe ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J1949 ;37:161-86.
29.
Casale PN, Devereux RB, Kligfield P. et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol1985;6:572-80.
30.
Casale PN, Devereux RB, Alonso DR, Campo E., Kligfield P.Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation1987;75:565-72.
31.
Molloy TJ, Okin PM, Devereux RB, Kligfield P.Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol1992;20:1180-86.
32.
Thurmann PA , Kenedi P., Schmidt A. et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension . Circulation1998;98:2037-42.
33.
Anan F., Takahashi N., Ooie T., Hara M., Yoshimatsu H., Saikawa T.Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Metabolism2004;53:777-81.
34.
Koren MJ, Devereux RB, Casale PN et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med1991;114:345-52.
35.
Spratt JC, Webb DJ, Shiels A., Williams B.Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects. JRAAS2001;2:227-32.
36.
Bella JN, Devereux RBIs echocardiography essential in the management of newly diagnosed hypertension?Am J Hypertens2006;19:1156-7.
37.
Okin PM, Devereux RB, Gerdts E. et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation2006;113:1588-96.
